In breve
Clinical trials are investigating ARLOCABTAGENE AUTOLEUCEL in people with multiple myeloma and in long-term follow-up after earlier gene-modified T-cell treatment. These studies look at safety, long-term effects, and how well the treatment works in adults and some pediatric patients. One trial also compares it with standard treatments in relapsed or refractory disease.
Punti chiave
- Clinical trials of ARLOCABTAGENE AUTOLEUCEL are studying people with relapsed or refractory multiple myeloma and people who had earlier gene-modified T-cell treatment. One study is Phase 3 and compares the treatment with standard options in multiple myeloma. Another study is Phase 4 and follows patients for long-term safety, persistence of the therapy, and later health effects. The trials include adults and, in the follow-up study, children who received gene-modified T cells in a previous study. Main outcomes include progression-free survival, complete response, delayed side effects, and long-term safety checks. In children, growth and sexual maturity are also tracked over time.
Overview of the trials
Two clinical trials in the provided data are linked to ARLOCABTAGENE AUTOLEUCEL. One is a long-term follow-up study for people who already received a genetically modified T-cell infusion in an earlier Celgene-sponsored study, and the other is a Phase 3 study in relapsed or refractory multiple myeloma exposed to lenalidomide.
Both studies are interventional, which means they involve planned treatment or follow-up steps rather than only observation.
Long-term follow-up study
The study NCT03435796 is an authorised Phase 4 long-term follow-up protocol for subjects treated with gene-modified T cells. It plans to enroll adult and paediatric subjects who received at least one genetically modified T-cell infusion in a previous Celgene-sponsored study.
The main goal is to watch for delayed adverse events, meaning side effects that appear later after treatment, including neurologic, autoimmune, hematologic, infectious, and hospitalization-related events. The study also checks whether the gene-modified T-cell products stay in the body over time and, for one cohort, whether there is any replication competent lentivirus, which is a safety check for a virus that could still copy itself.
For children, the study also follows physical growth and sexual maturity, and it continues until Tanner stage 5 is reached. The assessments begin 3 months after the last infusion, continue every 6 months until month 60, and then happen once a year until the end of the study, with a total safety and efficacy follow-up of up to 15 years from the last infusion.
Phase 3 study in relapsed or refractory multiple myeloma
The study NCT06615479 is an authorised Phase 3 trial in participants with relapsed or refractory multiple myeloma who have been exposed to lenalidomide. It is designed to see if arlo-cel works better than standard treatments, specifically daratumumab with pomalidomide and dexamethasone or carfilzomib with dexamethasone.
This study includes a GPRC5D-directed CAR T cell therapy, listed in the source as GPRC5D-TARGETED CAR T, together with comparison treatment options and supportive medicines used in the study plan. The brief summary says the study compares the treatment using two main effectiveness measures.
Main outcomes being measured
In the long-term follow-up study, the main safety outcomes include delayed adverse events, persistence of the gene-modified T-cell product, analysis of vector integration sites in one cohort, and incidence of RCL in one cohort. The study also looks at overall survival in participants whose original diagnosis was a malignancy, and at the proportion of subjects who progressed during the study.
In the Phase 3 multiple myeloma study, the main outcomes are progression-free survival, which means the time before the disease gets worse, and minimal residual disease-negative complete response, which means no signs of myeloma can be found in the body.
Who can take part
The long-term follow-up study includes all adult and paediatric subjects who had at least one genetically modified T-cell infusion in a previous Celgene-sponsored study. This makes it a follow-up group rather than a new treatment group.
The Phase 3 myeloma study includes participants with relapsed or refractory disease who have already been exposed to lenalidomide. The trial is focused on people whose myeloma has come back or has not responded well to earlier treatment.
Simple explanation of key terms
Interventional study means the researchers give a planned treatment or follow-up schedule and then measure the results.
Authorised means the study has been approved to run.
Enrollment is the number of people planned for the study, which is 1410 in the long-term follow-up trial and 440 in the Phase 3 myeloma trial.
Overall survival means how long people live after entering the study.
Vector integration sites are places in the body’s cells where the gene therapy material has inserted, and the study checks these for safety.